Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Sabin Inactivated Poliovirus Vaccine in Infants and Children
NCT05432141Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (6 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine. Started Jun 2022; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT05432141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432141.